Deborah A. Smith

Phase I Safety, Pharmacokinetics, and Clinical Activity Study of Lapatinib (GW572016), a Reversible Dual Inhibitor of Epidermal Growth Factor Receptor Tyrosine Kinases, in Heavily Pretreated Patients With Metastatic Carcinomas

Howard A. Burris, Herbert I. Hurwitz, Elizabeth Claire Dees et al. · Journal of Clinical Oncology · 2005 · 620 citations · Full text

Anti-interleukin-5 antibody treatment (mepolizumab) in active eosinophilic oesophagitis: a randomised, placebo-controlled, double-blind trial

Alex Straumann, Sébastien Conus, Pascale Grzonka et al. · Gut · 2009 · 579 citations · Full text

An Antibody Against IL-5 Reduces Numbers of Esophageal Intraepithelial Eosinophils in Children With Eosinophilic Esophagitis

Amal Assa’ad, Sandeep K. Gupta, Margaret H. Collins et al. · Gastroenterology · 2011 · 424 citations · Full text

Allergy, Esophageal Intraepithelial Eosinophils, Immunodeficiencies +6

Role of the Hog1 Stress-activated Protein Kinase in the Global Transcriptional Response to Stress in the Fungal Pathogen<i>Candida albicans</i>

Brice Enjalbert, Deborah A. Smith, Michael Cornell et al. · Molecular Biology of the Cell · 2005 · 377 citations · Full text

Fungal Cell Biology, Genetics, Gene Regulatory Network +21

Study of the Biologic Effects of Lapatinib, a Reversible Inhibitor of ErbB1 and ErbB2 Tyrosine Kinases, on Tumor Growth and Survival Pathways in Patients With Advanced Malignancies

Neil L. Spector, Wenle Xia, Howard A. Burris et al. · Journal of Clinical Oncology · 2005 · 363 citations · Full text